Weekly Digest - March 2025

Weekly Digest - March 2025

20 Mar 2025: Elevation Oncology to discontinue development of EO-3021, advancing EO-1022 while evaluating strategic options

  • Elevation Oncology will discontinue development of EO-3021, a Claudin 18.2 ADC, after Phase 1 trial data showed insufficient efficacy for a competitive benefit-risk profile 
  • The company will focus on advancing EO-1022, a HER3 ADC with glycan site-specific conjugation, and plans to present preclinical data at the AACR Annual Meeting in 2025 
  • EO-1022’s IND application is expected to be filed in 2026 
  • The clinical trial for EO-3021 showed a 22.2% ORR and 72.2% DCR, but the results did not meet the company’s success criteria
  • Elevation Oncology will reduce its workforce by approximately 70%, extending its cash runway into the second half of 2026 while exploring strategic options 

For full story click  here 

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home